You are here: Industry Insights > oral mucositis

News List

MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer prnasia
April 06, 2021
MitoImmune Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for MIT-001, an innovative new drug candidate for the treatment of oral mucositis.
Rapid relief of pain in oral mucositis, New episil oral liquid approved in China firstwordpharma
February 23, 2019
Oral mucositis (OM) is a common side effect, which occurs in 20%-40% of chemotherapy, approximately 80% of high-dose chemotherapy (such as hematopoietic stem cell transplantation pretreatment) and most of head and neck cancer patients receiving radiothera
Monopar receives licence to develop Onxeo’s Validive oral mucositis treatment pharmaceufical-technology
September 15, 2017
Onxeo is a clinical-stage biotechnology company that focuses on the development of new therapies to treat orphan diseases, particularly within oncology.